Gilead Sciences (NASDAQ:GILD)

Biotechnology word cloud

Short Sellers Become More Focused in Major Biotechs

The short interest data are out for the August 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
ten dollar bills

Projected Prices Where Investors Are Interested: Apple, JPMorgan, Ford, GE, Gilead

Despite periods of major volatility like you saw on Monday morning, the reality is that investors just do not often get to play in the extreme volatility. You may have ...
Read Full Story »
Biotechnology word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the July 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech

Should Gilead Really Be Rated Underperform?

Most analysts seem to be behind the growth that Gilead Sciences Inc. (NASDAQ: GILD) has seen, namely in its Hepatitis C vaccines (HCV) Harvoni and Solvaldi. For the most part ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Amazon, Citrix, Gilead, Sirius XM, 3D Systems, Twitter, Yelp and Many More

Stocks were indicated higher on Wednesday ahead of the pending FOMC decision on interest rates. Tuesday's rally was yet another instance where investors proved that they want to buy stocks ...
Read Full Story »
gilead

Gilead Tops Estimates in 2Q

Gilead Sciences Inc. (NASDAQ: GILD) reported second-quarter financial results Tuesday after the markets closed. The biotech giant had $3.15 in earnings per share (EPS) on $8.2 billion in revenue compared ...
Read Full Story »
biotech

Short Sellers Back Off Major Biotechs

The short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

Pharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc. ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Alarm.com, Pandora, PayPal, SanDisk, SunEdison, Tesla, AMD and More

Stocks were looking for direction on Tuesday as the earnings onslaught begins. One trend that has held up for almost four years now is that investors have bought every stock ...
Read Full Story »
Biotechnology word cloud

Short Sellers Back Off Big Biotech

The short interest data are out for the June 30 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
gilead

Is Gilead Headed Lower From Here?

Merrill Lynch recently updated its view on Gilead Sciences Inc. (NASDAQ: GILD). The firm maintained its Underperform rating for the stock but raised its price objective to $101 from $94, ...
Read Full Story »
DNA

Short Sellers Get More Selective on Big Biotech

The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Biotechnology word cloud

Short Sellers Lose Some Conviction Against Big Biotech

The short interest data are out for the May 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Biotechnology word cloud

Short Sellers Get Even More Ambitious Against Biotech Leaders

The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
GettyImages_183162370

Large Companies With Fastest Revenue and Earnings Growth in 2015

This year is nearing the halfway mark and analysts are beginning to project their biggest winners and losers on the year. S&P Capital IQ recently released a report regarding the ...
Read Full Story »